← All companies

AbInitio Bio

Active

The Intelligence layer for Drug Manufacturing

P26·Spring 2026·Healthcare·Boston, MA, USA·Team of 2·Founded 2026
Website ↗YC page ↗LinkedIn ↗

About

Abinitio Bio builds foundation models for biomanufacturing, validated against wet lab data. Our first model, Echo, predicts manufacturing outcomes more accurately than standard models, and any pharma or CDMO can adapt it to their own workflow instantly. By making process decisions that take 6-18 months today in hours, we help teams avoid the cost of delay on a single program.

Founders

  • Daniel Mukasa· Founder & CEO

    Founder & CEO at AbInitio Bio (YC P26). Postdoctoral Fellow at MIT focused on AI and drug discovery. Previously AI/ML intern at Merck working on antibody therapeutic design. PhD in Applied Physics and Materials Science from Caltech.

    LinkedIn ↗Twitter ↗

Change history · 3 recorded

  1. June 21, 2026
    • Location updated07:00 PM
  2. June 12, 2026
    • Tags updated07:00 PM
  3. June 10, 2026
    • Team grew from 1 to 207:00 PM